These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34206856)

  • 1. High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
    Willscher E; Hopp L; Kreuz M; Schmidt M; Hakobyan S; Arakelyan A; Hentschel B; Jones DTW; Pfister SM; Loeffler M; Loeffler-Wirth H; Binder H
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 12. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Björkblom B; Wibom C; Eriksson M; Bergenheim AT; Sjöberg RL; Jonsson P; Brännström T; Antti H; Sandström M; Melin B
    Neuro Oncol; 2022 Sep; 24(9):1454-1468. PubMed ID: 35157758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
    Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations in older patients with diffuse astrocytic gliomas.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Dec; 49():151653. PubMed ID: 33137656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.